Compile Data Set for Download or QSAR
Report error Found 11 Enz. Inhib. hit(s) with all data for entry = 11141
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408717(US10364238, Example 41 | N-[(3-fluoro-4-methoxypy...)
Affinity DataIC50: 3.30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50: 6.70nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408717(US10364238, Example 41 | N-[(3-fluoro-4-methoxypy...)
Affinity DataIC50: 4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408717(US10364238, Example 41 | N-[(3-fluoro-4-methoxypy...)
Affinity DataIC50: 4.00E+4nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM408717(US10364238, Example 41 | N-[(3-fluoro-4-methoxypy...)
Affinity DataIC50: 4.00E+4nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50: 4.00E+4nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetCoagulation factor XI(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50: 4.00E+4nMAssay Description:FXIa inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50: 4.00E+4nMAssay Description:Factor XIIa inhibitory activity in vitro was determined using standard published methods (see e.g. Shori et al., Biochem. Pharmacol., 1992, 43, 1209;...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetPlasminogen(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50: 4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetProthrombin(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50: 4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent

TargetSerine protease 1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM528099(1-({4-[(5-fluoro-2-oxopyridin-1-yl)methyl]phenyl}m...)
Affinity DataIC50: 4.00E+4nMAssay Description:Human serine protease enzymes plasmin, thrombin and trypsin were assayed for enzymatic activity using an appropriate fluorogenic substrate. Protease ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/9/2023
Entry Details
Go to US Patent